Skip to content
Yog Pharma
Metabolic and endocrineXanthine oxidase inhibitor

Allopurinol is a xanthine oxidase inhibitor indicated for gout, hyperuricemia during cancer therapy and recurrent calcium oxalate calculi. We supply it to US manufacturers of tablets and injection.

CAS315-30-0136.1 g/molC5H4N4O
2D structure of Allopurinol.

Data from PubChem (CID 135401907) and FDA’s substance registry

CAS number

315-30-0

Molecular formula

C5H4N4O

Molecular weight

136.1g/mol

FDA UNII

IUPAC name

1,5-dihydropyrazolo[5,4-d]pyrimidin-4-one

InChIKey

OFCNXPDARWKPPY-UHFFFAOYSA-N

Appearance
Fluffy white to off-white powder.
Solubility
Very slightly soluble in water and alcohol. Solubility in water at 37 °C is 80 mg/dL, and is greater in alkaline solution.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

A long-established API with a short specification. Bulk density and flow are what usually differ between sources.

On the US market

Reference product
ZyloprimNDA 016084
Approved ANDAs
12 with a marketed product
Approved forms and strengths
  • Tablet 100 mg, 200 mg, 300 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com